Effect of partial fatty acid oxidation inhibition with trimetazidine on mortality and morbidity in heart failure: Results from an international multicentre retrospective cohort study

Gabriele Fragasso, Giuseppe Rosano, Sang Hong Baek, Hamayak Sisakian, Pericle Di Napoli, Luca Alberti, Giliola Calori, Seok Min Kang, Laura Sahakyan, Armen Sanosyan, Cristiana Vitale, Giuseppe Marazzi, Alberto Margonato, Romualdo Belardinelli

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

Objectives: The aim of this cohort study was to retrospectively evaluate, in patients with chronic heart failure (CHF), the long term effect of trimetazidine (TMZ) on morbidity and mortality. Background: Previous small studies in patients with CHF have shown that TMZ can improve left ventricular function, exercise capacity and NYHA class compared to placebo. However, no data on the effects of TMZ on survival in patients with CHF have ever been produced. Methods: In this international multicentre retrospective cohort study data from 669 patients were analyzed. 362 patients were on TMZ due to symptom persistence despite up-titration of optimal CHF therapy, while the remaining patients continued conventional CHF therapy alone. Propensity score analysis was performed in order to minimize selection bias between the two groups. Results: Kaplan-Meier analysis for global mortality showed 11.3% improved global survival (p = 0.015) and 8.5% improved survival for cardiovascular (CVD) death (p = 0.050) in the TMZ group. Cox regression analysis for global mortality showed a significant risk reduction for TMZ treated patients with a hazard ratio (HR) = 0.189 (confidence interval - CI 95%: 0.017-0.454; p = 0.0002). TMZ also showed a good risk reduction profile for CVD death causes (HR = 0.072, CI 95%: 0.019-0.268, p = 0.0001). The rate of hospitalization for cardiovascular causes was reduced by 10.4% at 5 years (p < 0.0005) with increased hospitalization-free survival of 7.8 months. Conclusion: TMZ is effective in reducing mortality and event-free survival in patients with CHF. The addition of TMZ on top of optimal medical therapy improves long term survival in CHF patients.

Original languageEnglish
Pages (from-to)320-325
Number of pages6
JournalInternational Journal of Cardiology
Volume163
Issue number3
DOIs
Publication statusPublished - 2013 Mar 10

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Effect of partial fatty acid oxidation inhibition with trimetazidine on mortality and morbidity in heart failure: Results from an international multicentre retrospective cohort study'. Together they form a unique fingerprint.

  • Cite this

    Fragasso, G., Rosano, G., Baek, S. H., Sisakian, H., Di Napoli, P., Alberti, L., Calori, G., Kang, S. M., Sahakyan, L., Sanosyan, A., Vitale, C., Marazzi, G., Margonato, A., & Belardinelli, R. (2013). Effect of partial fatty acid oxidation inhibition with trimetazidine on mortality and morbidity in heart failure: Results from an international multicentre retrospective cohort study. International Journal of Cardiology, 163(3), 320-325. https://doi.org/10.1016/j.ijcard.2012.09.123